| Schedule of common stock sold to related parties |
As part of the registered direct offering, the following number of shares of common stock, pre-funded warrants and common warrants were sold to related parties: | | | | | | | | | | | | | | | Number of | | Number of | | Number of | | Aggregate | | | | Shares of | | Pre-Funded | | Common | | Purchase | | | Common Stock | | Warrants | | Warrants | | Price | OrbiMed Advisors LLC (1) | | | — | | | 1,444,085 | | | 1,397,684 | | $ | 2,499,856 | Puissance Capital Management (2) | | | 866,451 | | | — | | | 838,610 | | | 1,500,000 | Richard A. Miller, M.D. (3) | | | 577,634 | | | — | | | 559,073 | | | 1,000,000 | William B. Jones, Ph.D. (4) | | | 20,001 | | | — | | | 19,357 | | | 34,624 |
| (1) | Peter Thompson, M.D., a member of the Company’s Board of Directors since November 2014, is a Private Equity Partner at OrbiMed Advisors, LLC. |
| (2) | Ted Wang, Ph.D., a Co-Founder, General Manager and Director of Angel Pharmaceuticals, of which the Company holds a 49% ownership interest, is the founder of Puissance Capital Management. |
| (3) | Richard A. Miller, M.D. is the Company’s President, Chief Executive Officer and Chairman of the Board of Directors. |
| (4) | William B. Jones, Ph.D. is the Company’s Senior Vice President, Pharmaceutical Development. |
During the three months ended June 30, 2025, all of the common warrants sold to related parties as part of the Company’s May 2024 registered direct offering were exercised. The details of these exercises are as follows: | | | | | | | | | | | | | | Number of | | | | | Number of | | Common Shares | | | Aggregate | | | Common Warrants | | Issued Upon | | Proceeds Received | | | Exercised | | Exercise | | Upon Exercise | OrbiMed Advisors LLC (1) | | | 1,397,684 | | | 221,352 | | $ | — | Puissance Capital Management | | | 838,610 | | | 838,610 | | | 2,935,135 | Richard A. Miller, M.D. | | | 559,073 | | | 559,073 | | | 1,956,756 | William B. Jones, Ph.D. | | | 19,357 | | | 19,357 | | | 67,750 |
| (1) | OrbiMed Advisors LLC paid the exercise price of $3.50 per common stock warrant on a cashless basis, resulting in the Company withholding 1,176,332 of the warrant shares to pay the exercise price and issuing to OrbiMed Advisors LLC the remaining 221,352 shares. This transaction is considered a non-cash financing activity. |
|